Does Rallies show 13F holders for DXCM?

Yes. Rallies tracks hedge fund and 13F ownership data for DXCM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DXCM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DXCM. It does not provide personalized investment advice.

DXCM (Dexcom) Stock Analysis - Hedge Fund Holdings

Dexcom (DXCM) is a publicly traded Healthcare sector company. As of May 21, 2026, DXCM trades at $70.76 with a market cap of $25.12B and a P/E ratio of 33.13. DXCM moved +6.60% today. Year to date, DXCM is +5.60%; over the trailing twelve months it is -18.20%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $80.10. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DXCM stock?

Hedge funds tracked by Rallies that own DXCM include Tiger Global, Orbimed Advisors, Soros Fund, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Dexcom.

DXCM Key Metrics

Key financial metrics for DXCM
Metric	Value
Price	$70.76
Market Cap	$25.12B
P/E Ratio	33.13
EPS	$2.14
Dividend Yield	0.00%
52-Week High	$93.25
52-Week Low	$54.11
Volume	9.83M
Avg Volume	0
Revenue (TTM)	$4.66B
Net Income	$836.30M
Gross Margin	60.10%

Top Hedge Funds Holding DXCM

Tiger Global holds 1.15M shares of DXCM, changed +0.00% as of Jun 30, 2024.
Orbimed Advisors holds 289.90K shares of DXCM, changed +106.63% as of Jun 30, 2024.
Soros Fund holds 166.80K shares of DXCM, changed +233.60% as of Jun 30, 2024.
Bridgewater Associates holds 139.69K shares of DXCM, changed -6.42% as of Mar 31, 2026.
Pinebridge Investments holds 45.72K shares of DXCM, changed +80.58% as of Dec 31, 2024.

Latest DXCM News

Dexcom Upgraded to Buy on Forecasted Gross Margin Increase through 2026 — May 12, 2026
DexCom drops as CMS reimbursement-risk chatter revives pricing pressure fears — May 4, 2026
DexCom jumps as Q1 revenue climbs 15% and 2026 margin outlook rises — May 1, 2026
Dexcom Grows Q1 Revenue 15% to $1.2B, Keeps FY26 Outlook Unchanged — May 1, 2026
Dexcom Q1 Revenue Up 15%, Gross Margin Climbs to 63.5% — May 1, 2026

Recent DXCM Insider Trades

Heller Bridgette P sold 1.01K (~$60.73K) on May 12, 2026.
Brown Michael Jon sold 1.70K (~$107.17K) on Apr 15, 2026.
Brown Michael Jon sold 1.70K (~$110.24K) on Mar 16, 2026.

DXCM Analyst Consensus

21 analysts cover DXCM: 0 strong buy, 19 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.10.

Common questions about DXCM

Who owns DXCM stock?: Hedge funds tracked by Rallies that own DXCM include Tiger Global, Orbimed Advisors, Soros Fund, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Dexcom.
Does Rallies show 13F holders for DXCM?: Yes. Rallies tracks hedge fund and 13F ownership data for DXCM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DXCM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DXCM. It does not provide personalized investment advice.